Shield Therapeutics plc (SHIEF)
Shield Therapeutics plc operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Gateshead, GH, GB. The stock last traded at $0.09, up 0.00% on the session, giving a market capitalisation of $91.6M. On trailing twelve-month figures it carries a trailing P/E of -7.03, a net margin of -17.8%. Its beta of 1.72 implies it has historically moved more than the broad market.
Shield Therapeutics plc operates as a specialized pharmaceutical firm, dedicated to developing and bringing to market advanced clinical therapies that address significant unfulfilled medical requirements. Its flagship product, Accrufer/Feraccru, offers an innovative, non-salt-based oral treatment specifically for adults suffering from iron deficiency, irrespective of whether anemia is present. Furthermore, the company is advancing PT20, a pioneering iron-based phosphate binder that has successfully concluded its pivotal Phase II trials for managing hyperphosphatemia in individuals with chronic kidney disease. This enterprise was founded in 2008 and maintains its headquarters in Gateshead, United Kingdom.
Shield Therapeutics plc is most often compared with the following Healthcare names: